Clinical Trial Update: A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating efficacy and safety of MGL-3196 (Resmetirom) in patients with NASH and fibrosis is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• MGL-3196 (resmetirom)

Snippet

Sponsor: Madrigal Pharmaceuticals, Inc. | Conditions: NASH - Nonalcoholic Steatohepatitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING